FDA Section 524B Cybersecurity Requirements: What Medical Device Companies Must Know Now

FDA's Cybersecurity Mandate Is No Longer Optional

If you are developing a connected medical device or preparing a premarket submission, Section 524B of the Federal Food, Drug, and Cosmetic Act has fundamentally changed your regulatory obligations. Enacted through the Consolidated Appropriations Act of 2023 and effective March 29, 2023, Section 524B gives FDA explicit statutory authority to require cybersecurity information as part of any premarket submission for a cyber device. This is not a guideline recommendation. It is federal law.

For founders and regulatory professionals at small and mid-sized device companies, understanding exactly what FDA expects — and how to build a defensible submission — is now a prerequisite for market entry. This post breaks down the core requirements, the regulatory framework you need to understand, and the practical steps to get compliant.

What Is a Cyber Device Under Section 524B?

Section 524B defines a cyber device as a device that includes software validated, installed, or authorized by the manufacturer; has the ability to connect to the internet; and contains any technological characteristics that could be vulnerable to cybersecurity threats. In practice, this captures the vast majority of modern connected devices — from insulin pumps and cardiac monitors to hospital-networked imaging systems and Software as a Medical Device (SaMD).

If your device communicates over Wi-Fi, Bluetooth, Ethernet, or any network protocol, assume Section 524B applies to your submission. Attempting to argue out of this definition during review is a losing strategy that will cost you time and clearance cycles.

What FDA Now Requires in Your Premarket Submission

Under Section 524B and FDA's March 2023 guidance document, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, sponsors must provide four core deliverables in every applicable 510(k), PMA, De Novo, or EUA submission:

• A plan to monitor, identify, and address postmarket cybersecurity vulnerabilities on a reasonably justified regular cycle throughout the device's total product life cycle (TPLC).
• Processes and procedures to provide reasonably justified updates and patches to the device and related systems, including a commitment to do so on a critical basis as needed.
• A Software Bill of Materials (SBOM) that includes commercial, open-source, and off-the-shelf software components. FDA expects this to align with NTIA minimum elements and be updated throughout the product's lifecycle.
• Evidence that the device meets such other cybersecurity requirements as FDA may require through regulation or guidance, which currently includes threat modeling, architecture views, and security testing documentation.

The Secure Product Development Framework (SPDF)

FDA's 2023 premarket guidance strongly recommends implementing a Secure Product Development Framework (SPDF) as defined in NIST SP 800-218 and aligned with IEC 62443-4-1. The SPDF is not merely a checklist — it is a documented, repeatable process integrated into your Quality Management System under 21 CFR Part 820 (or ISO 13485) that governs how security is designed, tested, and maintained at every stage of development.

Reviewers at CDRH will look for evidence of threat modeling (FDA recommends STRIDE or similar methodologies), cybersecurity risk management that interfaces with your ISO 14971 risk management process, security architecture diagrams, and third-party penetration testing or vulnerability scanning results. Gaps in any of these areas are increasingly generating FDA Refuse to Accept (RTA) decisions and Additional Information requests that delay clearance by months.

Postmarket Obligations Under Section 524B

Section 524B is not a one-time submission requirement. FDA's 2022 postmarket cybersecurity guidance, Postmarket Management of Cybersecurity in Medical Devices, establishes that manufacturers must maintain a structured vulnerability management program across the device's entire commercial life. This includes coordinated vulnerability disclosure (CVD) policies, relationships with Information Sharing and Analysis Organizations (ISAOs), and defined response timelines — critical patches within 30 days, routine patches within 60 days where feasible.

These postmarket obligations must be reflected in your Design History File and Quality System procedures before submission. FDA reviewers are now checking for this alignment during premarket review, not just after a reportable cybersecurity event occurs.

Common Gaps That Delay Submissions

• Incomplete or missing SBOMs that do not address open-source dependencies or firmware components
• Threat models that are too high-level and fail to address specific attack surfaces for the device's intended use environment
• Security testing that lacks documented methodology, scope, or independent validation
• Risk management files that treat cybersecurity as separate from the ISO 14971 process rather than integrated
• No documented postmarket vulnerability management plan at the time of initial submission

Start Building Compliance Now

Section 524B compliance is not a documentation exercise you complete the week before submission. Building a defensible cybersecurity posture requires early integration into your design controls, risk management, and QMS infrastructure. The companies that navigate this well are those that engage regulatory and cybersecurity expertise during product development — not during remediation.

At ADB Consulting & CRO Inc., we help medical device companies at every stage structure their cybersecurity documentation, SBOM strategy, and premarket submissions to meet FDA's current expectations under Section 524B. Whether you are preparing your first 510(k) for a connected device or remediating a deficient submission, we bring the regulatory expertise to move you forward.

Book a free discovery call with Andre Butler at adbccro.com and get clarity on exactly where your cybersecurity submission stands — before FDA tells you.